The global veterinary clinical trials market size was valued at USD 5.42 billion in 2025 and is projected to grow from USD 5.88 billion in 2026 to USD 11.42 billion by 2034, registering a CAGR of 8.65% during the forecast period (2026–2034). North America dominated the veterinary clinical trials market with a market share of 34.19% in 2025.
The veterinary clinical trials market comprises research studies conducted to evaluate the safety, efficacy, and performance of veterinary drugs, vaccines, medical devices, and biologics before regulatory approval and commercialization. These trials are conducted across companion animals, livestock, and other species to support product development and ensure compliance with animal health regulations.
The veterinary clinical trials market demand is driven by the rising prevalence of animal diseases, growing pet ownership, and expanding livestock healthcare needs. Supportive regulatory frameworks and technological advancements in clinical research are also contributing to the veterinary clinical trials market growth.
Download a Free Sample To learn more about this report,
Decentralized and Digital-enabled Veterinary Clinical Trial Models
Veterinary clinical trials are increasingly shifting from site-centric studies to decentralized models supported by digital technologies. Remote monitoring tools, wearable animal health devices, telemedicine consultations, and electronic data capture platforms are improving trial efficiency while reducing the need for frequent veterinary hospital visits. This transition enhances owner participation, enables continuous health monitoring, and accelerates data collection for clinical research.
Growing Use of Precision Medicine in Veterinary Clinical Research
Veterinary clinical research is increasingly focusing on precision medicine by developing therapies tailored to specific genetic profiles, disease biomarkers, and animal breeds. Advances in genomic sequencing and molecular diagnostics are enabling researchers to identify targeted treatment approaches for conditions such as cancer, inherited disorders, and chronic diseases in companion animals. This shift is improving treatment efficacy while supporting the development of innovative therapeutics.
The veterinary clinical trials market forecasts continued investment activity driven by rising demand for innovative animal therapeutics and increasing collaboration between pharmaceutical companies, CROs, and academic veterinary institutions.
In January 2026, the Weill Family Foundation committed USD 120 million to the UC Davis School of Veterinary Medicine, marking the largest philanthropic donation ever made to a veterinary school. The funding will support the expansion of veterinary clinical research infrastructure, construction of a new small animal teaching hospital, and advancement of translational research capabilities.
Rising Animal Drug & Biologics Development and Growing Pet Ownership Drives Market
The increasing development of veterinary pharmaceuticals, vaccines, monoclonal antibodies, and biologics is driving demand for veterinary clinical trials. Animal health companies are expanding their research pipelines to address infectious diseases, chronic disorders, and emerging zoonotic threats across companion and livestock animals. This increases the need for well-designed clinical studies to demonstrate product safety and efficacy before regulatory approval.
The rising global population of companion animals and increasing expenditure on veterinary healthcare are driving demand for advanced treatment options, supporting growth in veterinary clinical trials. Pet owners are seeking innovative therapies for conditions such as cancer, osteoarthritis, dermatological disorders, and chronic diseases, encouraging manufacturers to invest in new product development. This growing demand expands the number of clinical studies conducted across veterinary hospitals and specialty research centers.
Limited Availability of Eligible Trial Participants and High Cost & Operational Complexity of Veterinary Clinical Trials Restrain Market Expansion
Veterinary clinical trials often face challenges in enrolling sufficient numbers of eligible animals due to strict inclusion criteria, owner consent requirements, and variations in disease prevalence. In addition, the limited number of specialized veterinary research hospitals and experienced investigators restricts trial capacity in many regions. This slows patient recruitment, delays study completion, and reduces the pace of veterinary product development and market adoption.
Veterinary clinical trials require significant investment in study design, patient recruitment, diagnostics, monitoring, regulatory compliance, and data management, making them costly for sponsors. Recruiting eligible animal participants and maintaining protocol compliance across multiple veterinary sites further increases operational complexity.
Increasing Development of Livestock Vaccines and Expansion of Regulatory Pathways for Novel Veterinary Therapeutics Offer Growth Opportunities to Market Players
The increasing focus on controlling transboundary animal diseases such as African Swine Fever (ASF), Foot-and-Mouth Disease (FMD), and Avian Influenza is creating significant opportunities for veterinary pharmaceutical companies and CROs. Governments and animal health organizations are investing in the development and clinical evaluation of next-generation vaccines and biologics to strengthen food security and disease surveillance.
Regulatory agencies are introducing streamlined pathways for innovative veterinary medicines, creating opportunities for sponsors, CROs, and research institutions to accelerate product development. Increasing approvals for monoclonal antibodies, gene-based therapies, regenerative medicine, and advanced biologics require specialized clinical trials to establish safety and efficacy. Companies including Elanco Animal Health and Zoetis are investing in novel therapeutic platforms, which are expected to expand the volume and complexity of veterinary clinical research over the coming years.
Limited Availability of Validated Clinical Endpoints and Managing Long-term Follow-up and Owner Compliance Challenges Market Growth
The absence of standardized clinical endpoints and validated biomarkers for many animal diseases makes it difficult to consistently measure treatment efficacy across veterinary clinical trials. This can result in variable study outcomes, longer validation timelines, and uncertainty during regulatory review. The development of disease-modifying therapies for canine osteoarthritis has been hindered by the lack of universally accepted objective biomarkers.
Many veterinary clinical trials require extended follow-up to evaluate treatment durability and long-term safety, particularly for chronic diseases and biologics. Maintaining pet owner engagement throughout the study period remains difficult, leading to missed assessments and incomplete datasets.
Request Customizationto receive a tailored report.
The companion animal segment accounted for a share of 61.47% in 2025, owing to rising pet ownership, increased spending on advanced veterinary care, and growing demand for clinical trials focused on chronic conditions such as cancer and osteoarthritis. Higher adoption of personalized therapies in dogs and cats further supports segment expansion.
The livestock animal segment is expected to grow at a CAGR of around 9.14% during the forecast period due to increasing demand for disease control vaccines, food-animal health management, and preventive veterinary solutions. Rising concerns regarding zoonotic outbreaks and productivity losses in cattle, poultry, and swine are encouraging more livestock-focused clinical research activities.
In 2025, oncology accounted for a share of 28.06% due to the rising prevalence of cancer in companion animals, increasing availability of veterinary oncology specialists, and growing development of targeted cancer therapies. Expansion of immunotherapy and molecular diagnostic applications is increasing clinical trial activity for animal cancer treatments.
The internal medicine segment is expected to grow at a CAGR of 9.42% during the forecast period, driven by increasing research on chronic disorders, metabolic diseases, and gastrointestinal conditions in animals. Growing adoption of advanced diagnostics and long-term therapeutic monitoring is supporting clinical trials for internal medicine applications.
The medicines segment accounted for a share of 53.60% in 2025, driven by increasing development of veterinary pharmaceuticals, rising demand for therapeutic drugs, and continuous introduction of vaccines and biologics. Regulatory approvals for novel animal medicines are encouraging pharmaceutical companies to conduct extensive clinical evaluations.
The medical device segment is expected to grow at a CAGR of 9.75% during the forecast period, due to rising adoption of veterinary surgical devices, diagnostic equipment, and implantable technologies. Increasing demand for minimally invasive procedures and advanced monitoring systems is driving clinical validation studies for veterinary medical devices.
The veterinary pharmaceutical & biopharmaceutical companies segment accounted for a share of 54.01% in 2025, owing to strong investment in drug pipelines, expanding biologics development, and increasing focus on novel animal therapeutics. These companies conduct extensive trials to support regulatory approvals and commercial launches.
The academic & research centers segment is expected to register a CAGR of 9.75% during the forecast period, driven by rising government-funded veterinary research, collaborative studies with industry players, and advancements in translational animal research. These institutions provide specialized expertise for early-stage therapeutic and disease investigation.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Advanced Veterinary Research Infrastructure and Strong Animal Health Innovation Ecosystem
The North America veterinary clinical trials market accounted for the largest regional share of 34.19% in 2025, driven by presence of leading animal health companies, advanced veterinary research institutions, and well-established regulatory frameworks for animal drug development. The region benefits from strong investment in companion animal therapeutics, increasing pet healthcare expenditure, and a high concentration of specialty veterinary hospitals conducting clinical studies.
The US veterinary clinical trials market was valued at USD 1.62 billion in 2025, driven by increasing development of veterinary pharmaceuticals, biologics, and precision medicine-based therapies. The country’s extensive network of veterinary colleges, specialty hospitals, and contract research organizations supports large-scale clinical trial execution across companion and livestock animals. According to the American Pet Products Association, the US continues to witness significant growth in pet ownership and veterinary spending, supporting demand for advanced clinical research services.
The veterinary clinical trials market in Canada was valued at USD 233.60 million in 2025, supported by increasing collaboration between universities and industry players, and rising demand for advanced veterinary therapeutics. The country’s strong livestock industry and expanding companion animal healthcare sector are creating opportunities for clinical studies related to vaccines, infectious diseases, and chronic animal disorders.
Asia Pacific: Fastest Growth Driven by Rising Animal Health Investments and Expansion of Veterinary Research Capabilities
The Asia Pacific veterinary clinical trials market is expected to grow at a CAGR of 10.38% during the forecast period, showcasing the fastest regional growth. Growth is supported by increasing government focus on livestock disease control, and rising investments in veterinary biotechnology infrastructure. The region benefits from large animal populations requiring preventive healthcare solutions. According to the FAO, Asia accounted for around 40% of global livestock production, creating significant demand for veterinary health innovation and clinical evaluation.
The China veterinary clinical trials market was valued at USD 304.52 million in 2025, supported by development of animal health products, rising livestock disease management requirements, and expansion of domestic veterinary pharmaceutical research. Government initiatives focused on food safety and animal disease prevention are encouraging clinical evaluation of vaccines and therapeutics. The country’s large livestock population and growing companion animal healthcare sector are creating demand for veterinary clinical trial services across multiple therapeutic areas.
The India veterinary clinical trials market was valued at USD 155.76 million in 2025, fueled by increasing demand for livestock vaccines, expanding veterinary pharmaceutical manufacturing, and rising research activities in animal disease management. Growth in dairy and poultry production is encouraging companies to develop preventive healthcare solutions requiring clinical validation.
The Japan veterinary clinical trials market was valued at USD 179.71 million in 2025, supported by advanced veterinary healthcare infrastructure, high adoption of companion animal therapies, and increasing demand for innovative treatments for aging pets. The country’s focus on precision veterinary medicine, oncology, and regenerative therapies is encouraging clinical research activities.
Unlock Regional Insightsto access country-level data, & regional trends.
The veterinary clinical trials market competitive landscape is moderately fragmented, with competition led by specialized CROs, animal health companies, academic veterinary institutions, and integrated research service providers. Key participants compete through therapeutic expertise, global trial site networks, regulatory knowledge, digital data management capabilities, and access to diverse animal populations. The veterinary clinical trials market ecosystem is shaped by evolving regulatory requirements, increasing investment in veterinary drug development, and rising demand for biologics and precision medicine.
September 2025: The Royal Veterinary College expanded its research collaboration efforts through organ-on-chip technology development, highlighting increasing adoption of advanced laboratory models in veterinary research.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Pavan Warade is a Research Analyst with over 4 years of expertise in Technology and Aerospace & Defense markets. He delivers detailed market assessments, technology adoption studies, and strategic forecasts. Pavan’s work enables stakeholders to capitalize on innovation and stay competitive in high-tech and defense-related industries.
We are featured on:
sales@straitsresearch.com